The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression
Abstract
Objective: Severe obesity is a chronic inflammatory disease where various cytokines/adipocytokines play a key role. Pro-inflammatory cytokines such as interleukin 6 (IL-6) and tumour necrosis factor-α (TNFα) are produced by human adipose tissue dependent on the degree of obesity. Mouse studies suggest a key role of adipose tissue-derived IL-6 in hepatic insulin resistance via modification of liver suppressor of cytokine signalling 3 (SOCS-3) expression. Design and methods: We examined the effect of excessive weight loss on systemic levels, subcutaneous and visceral adipose tissue and liver expression of IL-6 and TNFα in 20 severely obese patients undergoing laparoscopic adjustable gastric banding (LAGB). Furthermore, we studied liver expression of SOCS3, an important regulator of insulin resistance, and fat tissue expression of the anti-inflammatory adipocytokine adiponectin and its receptors. Serum and tissue samples were collected before and 6 months after LAGB surgery. Results: IL-6/TNFα mRNA expression before weight loss were similar in subcutaneous and visceral adipose tissue and much higher compared to hepatic expression. Subcutaneous adipose tissue mRNA expression of both pro-inflammatory cytokines, but especially of IL-6 decreased dramatically after extensive weight loss whereas expression of adiponectin and its receptors increased. Weight loss also led to a significant reduction in liver IL-6 expression, whereas liver TNFα mRNA expression did not change. IL-6 and C-reactive protein serum levels decreased after weight loss whereas TNFα serum levels were below the detection limit before and after surgery. These effects were paralleled by reduced hepatic SOCS3 expression and improved insulin resistance 6 months after LAGB surgery. Conclusion: Expression of IL-6 and TNFα mRNA is more pronounced in adipose compared to liver tissue in patients with severe obesity. Our results highlight excessive weight loss as a successful anti-inflammatory strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“All our study patients had moderate-to-severe liver steatosis and 25% evidence of non-alcoholic steatohepatitis (data not shown).(32) However, the liver might indeed be the key target organ for these elevated IL-6 and TNFa levels, as continuous IL-6/TNFa exposure affects hepatic insulin resistance via upregulation of…”
BackgroundInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 1×
“Adipose tissue secretes a variety of bioactive mediators including adipocytokines such as adiponectin, leptin, resistin, pre-B-cell enhancing factor/Nampt/visfatin or classical cytokines such as the pro-inflammatory mediators tumour necrosis factor a (TNFa) and interleukin 6 (IL-6).(1) 2 A first link between obesity a…”
BackgroundAdipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“by inflammatory signal transducers such as c-Jun N-terminal kinase (JNK1) or inhibitor of nuclear factor-kB kinase-b (IKKb) is considered one of the key aspects that disrupts insulin signalling.(8) TNFa and IL-6 have both been demonstrated to be involved in the pathophysiology of insulin resistance.”
BackgroundAdipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1937 · Cited by 3,188
Self-citationNovel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin
Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2473 · Cited by 2,147
Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-α,in Vivo1
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., & Coppack, S. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4450 · Cited by 2,012
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P., & Bahouth, S. W. (2004) · Endocrinology · doi:10.1210/en.2003-1336 · Cited by 1,572
Cited by
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Self-citationZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Self-citationTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationMagkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886
“…with greater weight loss, e.g., after bariatric surgery-induced 20% weight loss that has been associated with decreased gene expression of pro-inflammatory cytokines and macrophage number in adipose tissue of people with obesity (Bradley et al., 2012; Cancello et al., 2005; Moschen et al., 2010).”
Microbiota and diabetes: an evolving relationship
Tilg, H., & Moschen, A. R. (2014) · Gut · doi:10.1136/gutjnl-2014-306928 · Cited by 853
Self-citationTargher, G., Byrne, C. D., & Tilg, H. (2020) · Gut · doi:10.1136/gutjnl-2020-320622 · Cited by 827
Self-citationGut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525
Self-citationNon-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Self-citationMultiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Tilg, H., Adolph, T. E., & Moschen, A. R. (2021) · Hepatology · doi:10.1002/hep.31518 · Cited by 426
Self-citationMolecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus
Burhans, M. S., Hagman, D. K., Kuzma, J. N., Schmidt, K. A., & Kratz, M. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c170040 · Cited by 373
Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation
Moschen, A. R., Adolph, T. E., Gerner, R. R., Wieser, V., & Tilg, H. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.01.003 · Cited by 359
Self-citationTilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
Self-citationA vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
Chen, Z., Yu, R., Xiong, Y., Du, F., & Zhu, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0572-9 · Cited by 316
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310
Self-citationCurrent treatment paradigms and emerging therapies for NAFLD/NASH
Raza, S. (2021) · Frontiers in Bioscience · doi:10.2741/4892 · Cited by 310
Mechanistic Links Between Obesity, Diabetes, and Blood Pressure: Role of Perivascular Adipose Tissue
Saxton, S. N., Clark, B. J., Withers, S. B., Eringa, E. C., & Heagerty, A. M. (2019) · Physiological Reviews · doi:10.1152/physrev.00034.2018 · Cited by 272
Shehzad, A., Ha, T., Subhan, F., & Lee, Y. S. (2011) · European Journal of Nutrition · doi:10.1007/s00394-011-0188-1 · Cited by 271
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Hou, X., Yin, S., Ren, R., Liu, S., Yong, L., Liu, Y., Li, Y., Zheng, M., Kunos, G., Gao, B., et al. (2021) · Hepatology · doi:10.1002/hep.31658 · Cited by 223
Metabolic adaptation in obesity and type ii diabetes: myokines, adipokines and hepatokines
Oh, K.-J., Lee, D., Kim, W., Han, B., Lee, S., & Bae, K.-H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010008 · Cited by 210
Schmitz, J., Evers, N., Awazawa, M., Nicholls, H. T., Brönneke, H. S., Dietrich, A., Mauer, J., Blüher, M., & Brüning, J. C. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2015.12.001 · Cited by 148
Obesity-induced lymphatic dysfunction is reversible with weight loss
Nitti, M. D., Hespe, G. E., Kataru, R. P., García Nores, G. D., Savetsky, I. L., Torrisi, J. S., Gardenier, J. C., Dannenberg, A. J., & Mehrara, B. J. (2016) · The Journal of Physiology · doi:10.1113/jp273061 · Cited by 103
“…loss is known to improve glucose intolerance and insulin sensitivity, decrease expression of pro-inflammatory cytokines in adipose tissue, normalize expression of adipokines and improve cardiac function (Sjostrom et al. 2000, 2004; Poirier et al. 2003; Clement et al. 2004; Moschen et al. 2010).”
BackgroundGut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
The effects of bariatric surgeries on nonalcoholic fatty liver disease
Aldoheyan, T., Hassanain, M., Al-Mulhim, A., Al-Sabhan, A., Al-Amro, S., Bamehriz, F., & Al-Khalidi, H. (2017) · Surgical Endoscopy · doi:10.1007/s00464-016-5082-8 · Cited by 47
Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis
Morikawa, R., Nakamoto, N., Amiya, T., Chu, P.-S., Koda, Y., Teratani, T., Suzuki, T., Kurebayashi, Y., Ueno, A., Taniki, N., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.033 · Cited by 40
Schwenger, K. J. P., Fischer, S. E., Jackson, T., Okrainec, A., & Allard, J. P. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.06.007 · Cited by 36
Metadata
- Authors
- Moschen, A. R., Molnar, C., Geiger, S., Graziadei, I., Ebenbichler, C. F., Weiss, H., Kaser, S., Kaser, A., & Tilg, H.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-07-21
- Volume
- 59
- Issue
- 9
- Pages
- 1259-1264
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2112515812
- Cited by
- 267
- References
- 41
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.